Horse owner experiences and observations with the use of SGLT2i for the management of equine metabolic syndrome and hyperinsulinaemia‐associated laminitis

Equine Veterinary Education, Journal Year: 2024, Volume and Issue: unknown

Published: April 8, 2024

Summary Background Sodium‐glucose cotransporter 2 inhibitors (SGLT2i) are being used increasingly in equine practice. While there is emerging clinical evidence of the safety and efficacy these drugs, currently no reports to document owner experiences with treatment. Objective The objective study was report observations following treatment SGLT2i horses. Study design A cross‐sectional online survey. Methods Horse owners were recruited via social media, forums their veterinarians participate an anonymous survey when treating horses SGLT2i. Results Three hundred forty‐two responses met inclusion criteria. Ertugliflozin most commonly prescribed (79.8%), common reasons for high insulin concentrations (84.2%) active laminitis (59.7%). 85.3% reported had improved quality life after commencing treatment, while 9.4% change 5.3% a worsening signs. Of who considered euthanasia prior ( n = 77), 80.5% horse's level pain be either mild or absent 30 days 94.8% improved. Most 220, 64.7%) they extremely satisfied somewhat 72, 21.2%) Treatment concerns included safety/side effects, medication cost, availability long‐term efficacy. 114 (33.3%) one more initial adverse effects upon induction onto medication, particularly excessive urination 70, 20.5%), drinking 38, 11.1%), weight loss 34, 9.9%) dullness 26, 7.6%). Main limitation Sampling bias through media veterinary practices reliance on subjective reports. Conclusion use associated excellent rates satisfaction owner‐reported horse; however, some observed.

Language: Английский

---

Comparison of incident hypertension between SGLT2 inhibitors vs. DPP4 inhibitors

Hypertension Research, Journal Year: 2024, Volume and Issue: 47(7), P. 1789 - 1796

Published: April 10, 2024

Although several randomized clinical trials have reported the potential benefit of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in reducing blood pressure (BP), whether SGLT2i can reduce incident hypertension is unknown. We analyzed individuals with diabetes who were newly prescribed or dipeptidyl peptidase 4 (DPP4i) a large-scale epidemiological database. The primary outcome was incidence hypertension. A propensity score matching algorithm employed to compare subsequent development between and DPP4i groups. After matching, 5708 well-balanced pairs users identified. administration associated reduced risk (HR 0.91, 95% CI: 0.84-0.97). advantage use over for generally consistent sensitivity analyses, subgroup analyses showed that significantly lower men, patients baseline HbA1c <7.5%, systolic ≥127 mmHg. Our investigation using nationwide real-world data demonstrated diabetes.

Language: Английский

---

Effect of preceding drug therapy on the renal and cardiovascular outcomes of combined sodium‐glucose cotransporter‐2 inhibitor and glucagon‐like peptide‐1 receptor agonist treatment in patients with type 2 diabetes and chronic kidney disease

Diabetes Obesity and Metabolism, Journal Year: 2024, Volume and Issue: 26(8), P. 3248 - 3260

Published: May 19, 2024

Abstract Aim To conduct a post hoc subgroup analysis of patients with type 2 diabetes (T2D) from the RECAP study, who were treated sodium‐glucose cotransporter‐2 (SGLT2) inhibitor and glucagon‐like peptide 1 receptor agonist (GLP‐1RA) combination therapy, focusing only on those had chronic kidney disease (CKD), to examine whether composite renal outcome differed between received SGLT2 treatment first GLP‐1RA first. Methods We included 438 CKD (GLP‐1RA‐first group, n = 223; inhibitor‐first 215) 643 T2D in study. The incidence outcome, defined as progression macroalbuminuria and/or ≥50% decrease estimated glomerular filtration rate (eGFR), was analysed using propensity score (PS)‐matched model. Furthermore, we calculated win ratio for these outcomes, which weighted following order: (1) both eGFR macroalbuminuria; (2) only; (3) only. Results Using PS‐matched model, 132 each group paired. outcomes did not differ two groups 10%; 17%; odds 1.80; 95% confidence interval [CI] 0.85 4.26; p 0.12). GLP‐1RA‐first versus 1.83 (95% CI 1.71 1.95; < 0.001). Conclusion Although groups, significant. These results suggest that, addition an baseline may lead more favourable outcomes.

Language: Английский

---

Comparative Cardiovascular Outcomes of Dapagliflozin Versus Empagliflozin in Patients With Type 2 Diabetes: A Meta-Analysis

Cureus, Journal Year: 2025, Volume and Issue: unknown

Published: May 4, 2025

Sodium-glucose co-transporter-2 (SGLT2) inhibitors have demonstrated significant cardiovascular benefits in patients with type 2 diabetes. However, head-to-head comparisons between dapagliflozin and empagliflozin, two widely prescribed SGLT2 inhibitors, remain limited. This meta-analysis aimed to directly compare the outcomes of these agents We conducted a comprehensive literature search across multiple databases included eight retrospective studies enrolling 280,617 (158,352 receiving empagliflozin 122,265 dapagliflozin). The primary outcome was major adverse events (MACE), secondary including all-cause mortality, myocardial infarction, stroke. Our pooled analysis revealed no difference MACE risk (RR: 1.04; 95% CI: 0.96 1.13). Similarly, differences were observed for mortality 1.05; 1.15), infarction 0.94 1.16), or stroke 1.00; 0.91 1.09). Subgroup analyses by gender, atherosclerotic disease, chronic kidney disease status showed consistent results. heart failure, trend toward reduced 0.90; 0.82 1.00). Despite pharmacokinetic agents, our findings suggest comparable diabetes, potentially enhanced those failure. due lack studies, this finding should be interpreted caution. These results provide valuable insights clinical decision-making when selecting reduction diabetic patients. Further prospective are warranted confirm explore potential mechanistic agents.

Language: Английский

---

Tofogliflozin long-term effects on atherosclerosis progression and major clinical parameters in patients with type 2 diabetes mellitus lacking a history of cardiovascular disease: a 2-year extension study of the UTOPIA trial

Cardiovascular Diabetology, Journal Year: 2023, Volume and Issue: 22(1)

Published: June 22, 2023

This study aimed to assess the long-term effects of tofogliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, on atherosclerosis progression and major clinical parameters in patients with type diabetes lacking an apparent history cardiovascular disease.This was prospective observational 2-year extension "Using TOfogliflozin for Possible better Intervention against Atherosclerosis (UTOPIA)" trial, randomized intervention study. The primary endpoints represented changes carotid intima-media thickness (IMT). Secondary included brachial-ankle pulse wave velocity (baPWV) biomarkers glucose metabolism, lipid renal function, risks.The mean IMT common artery (IMT-CCA) significantly decreased both tofogliflozin (- 0.067 mm, standard error 0.009, p < 0.001) conventional treatment groups 0.080 SE throughout follow-up period; however, no significant intergroup differences (0.013 95% confidence interval (CI) - 0.012 0.037, = 0.32) were observed mixed-effects model repeated measures. baPWV increased group (82.7 ± 210.3 cm/s, 0.008) but not 17.5 221.3 0.54), resulting difference 100.2 CI 182.8 17.5, 0.018). Compared group, improved hemoglobin A1c high-density lipoprotein cholesterol levels, body mass index, abdominal circumference, systolic blood pressure. frequencies total serious adverse events did vary between groups.Tofogliflozin associated inhibition wall thickening exerted positive various risk factors while showing good safety profile.

Language: Английский

---